PMID- 18300794
OWN - NLM
STAT- MEDLINE
DCOM- 20080529
LR  - 20220331
IS  - 0147-5185 (Print)
IS  - 0147-5185 (Linking)
VI  - 32
IP  - 4
DP  - 2008 Apr
TI  - Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome 
      (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 
      patients.
PG  - 534-43
LID - 10.1097/PAS.0b013e31815ade45 [doi]
AB  - Patients affected by the multiple endocrine neoplasia type I syndrome (MEN1) 
      display a high incidence of pituitary adenomas, though it is still unknown 
      whether these pituitary tumors have specific pathologic features that would 
      distinguish them from sporadic pituitary adenomas. Pituitary tissue specimens of 
      77 MEN1 patients from the GTE (Groupe d'etude des Tumeurs Endocrines) register 
      were compared with unselected 2509 non-MEN1 sporadic pituitary tumors and also to 
      a control subgroup of 296 cases, where 1 MEN1 tumor was matched with 4 sporadic 
      tumors of the same hormonal immunoprofile. Sex, age, size, and invasiveness of 
      tumors, and menin gene mutations were documented. Histologic analysis took into 
      account 33 items, including immunocytochemical data, the proliferative marker 
      Ki-67, and an examination of the juxtatumoral pituitary. MEN1 tumors were 
      significantly larger and more often invasive by histology. MEN1 patients with 
      large pituitary tumors (grade IV) were younger than non-MEN1 patients. MEN1 
      tumors had no other characteristic histologic features and no predominance of any 
      one hormone producing subtype. However, plurihormonal adenomas versus 
      monohormonal and nonimmunoreactive adenomas were more frequent in MEN1 tumors 
      (39%) than in the control non-MEN1 group (P = 0.001). Especially, the growth 
      hormone and prolactin plurihormonality with unusual association with 
      follicle-stimulating hormone, luteinizing hormone, or adrenocorticotropic hormone 
      was more frequent in MEN1 tumors. In addition, multiple adenomas were 
      significantly more frequent (4% vs. 0.1%; P < 0.0001), especially 
      prolactin-adrenocorticotropic hormone. Somatotroph hyperplasia, with or without a 
      microadenoma was found in only 3 MEN1 patients, with growth hormone-releasing 
      hormone hypersecretion by a pancreatic tumor in 2 of them. All types of mutation 
      were observed, including frameshifts, nonsenses, missenses, and 1 case of 
      germline MEN1 encompassing large deletion, strongly suggesting the absence of any 
      phenotype-genotype correlation.
FAU - Trouillas, Jacqueline
AU  - Trouillas J
AD  - INSERM, U842, Lyon, F-69372, France. jacqueline.trouillas@recherche.univ-lyon1.fr
FAU - Labat-Moleur, Francoise
AU  - Labat-Moleur F
FAU - Sturm, Nathalie
AU  - Sturm N
FAU - Kujas, Michele
AU  - Kujas M
FAU - Heymann, Marie-Francoise
AU  - Heymann MF
FAU - Figarella-Branger, Dominique
AU  - Figarella-Branger D
FAU - Patey, Martine
AU  - Patey M
FAU - Mazucca, Marc
AU  - Mazucca M
FAU - Decullier, Evelyne
AU  - Decullier E
FAU - Verges, Bruno
AU  - Verges B
FAU - Chabre, Olivier
AU  - Chabre O
FAU - Calender, Alain
AU  - Calender A
CN  - Groupe d'etudes des Tumeurs Endocrines
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Ki-67 Antigen)
RN  - 0 (MEN1 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - 9002-62-4 (Prolactin)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
RN  - 9002-71-5 (Thyrotropin)
SB  - IM
MH  - Adenoma/chemistry/genetics/*pathology
MH  - Adolescent
MH  - Adrenocorticotropic Hormone/analysis
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Cell Proliferation
MH  - Female
MH  - Follicle Stimulating Hormone/analysis
MH  - Gene Expression Regulation, Neoplastic
MH  - Human Growth Hormone/analysis
MH  - Humans
MH  - Hyperplasia
MH  - Immunohistochemistry
MH  - Ki-67 Antigen/analysis
MH  - Luteinizing Hormone/analysis
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/chemistry/genetics/*pathology
MH  - Mutation
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Pituitary Gland/chemistry/*pathology
MH  - Pituitary Neoplasms/chemistry/genetics/*pathology
MH  - Prolactin/analysis
MH  - Proto-Oncogene Proteins/genetics
MH  - Thyrotropin/analysis
EDAT- 2008/02/28 09:00
MHDA- 2008/05/30 09:00
CRDT- 2008/02/28 09:00
PHST- 2008/02/28 09:00 [pubmed]
PHST- 2008/05/30 09:00 [medline]
PHST- 2008/02/28 09:00 [entrez]
AID - 10.1097/PAS.0b013e31815ade45 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2008 Apr;32(4):534-43. doi: 10.1097/PAS.0b013e31815ade45.